Article

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

2024-04-22

Abstract excerpt

In contrast to patients with B cell precursor acute lymphoblastic leukemia (BCP-ALL), patients with acute myeloid leukemia (AML) have not yet benefited from recent advances in targeted immunotherapy. Repurposing immunotherapies that have been successfully used to target other hematological malignancies could, in case of a shared target antigen, represent a promising opportunity to expand the immunotherapeutic opti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f0051476-d56f-57a9-807f-8fdef21aa81a
DOI: 10.1101/2024.04.19.590200

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemiaDOI 10.1101/2024.04.19.590200Read

Molecular signature of pediatric B-ALL determines outcomes post CD19 CAR-T cell therapySemantic proximity Read

CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy eraSemantic proximity Read

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.Semantic proximity Read

Treatment Outcome of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse by Anti-CD19 CAR-TSemantic proximity Read

Immunophenotypic and Molecular Cytogenetic Associations of CD19 Expression in Acute Myeloid Leukemias, including in the t(8;21) negative settingSemantic proximity Read

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARSemantic proximity Read

Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALLSemantic proximity Read

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALLSemantic proximity Read

Relapse/refractory paediatric B-ALL case with CD19 - phenotype switching indicating the importance of appropriate diagnostics approach and targeted treatment adjustment – case reportSemantic proximity Read

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial DiagnosisSemantic proximity Read